Study designed to rapidly assess drug’s ability to penetrate the blood-brain barrier in humansContinue reading
Author Archive: AZBio
Roche receives FDA approval for VENTANA ALK (D5F3) CDx Assay to identify lung cancer patients eligible for targeted treatment with LORBRENA (lorlatinib)
- About 235,000 people in the US will be diagnosed with lung cancer in 2021, with non-small cell lung cancer (NSCLC) accounting for 84 percent of all lung cancers1
- ALK — anaplastic lymphoma kinase — is an important biomarker found in NSCLC, and targeted therapies have been shown to dramatically improve progression-free survival compared to the previous standard of care2,3,4
- The VENTANA ALK (D5F3) CDx Assay5 is now FDA approved as a companion diagnostic in four targeted treatments, providing more options to lung cancer patients
Castle Biosciences Launches DecisionDx-Melanoma Integrated Test Result Utilizing Artificial Intelligence to Predict Individualized Risk
Newly validated i31-GEP algorithm integrates DecisionDx-Melanoma continuous score with clinicopathologic factors designed to provide a more precise, personalized likelihood of sentinel lymph node positivity
NIH starting enrollment for third trial of blood clotting treatments for COVID-19
The National Institutes of Health has launched the last of three Phase 3 clinical trials to evaluate the safety and effectiveness of blood thinners to prevent life-threatening blood clots in adults diagnosed with COVID-19. The first patient in the trial was enrolled on February 15.
Researchers at the Barrow Neurological Institute at Phoenix Children’s Hospital and the University of Utah Seek to Discover New Cerebral Palsy Genes
Datavant and the Cerebral Palsy Research Network Announce Partnership to Enable Investigation of Genetic Basis of Cerebral PalsyContinue reading
Jeffrey Kordower to lead ASU’s fight against neurodegenerative diseases
Arizona State University has announced the appointment of Jeffrey Kordower as the founding director of the ASU-Banner Neurodegenerative Disease Research Center and endowed chair as The Charlene and J. Orin Edson Distinguished Director at the Biodesign Institute.Continue reading
FDA Issues Emergency Use Authorization for Third COVID-19 Vaccine
-
Action Advances Fight Against COVID-19, Follows Comprehensive Evaluation of Available Safety, Effectiveness and Manufacturing Quality Information by FDA Career Scientists, Input from External Experts
HTG Concludes Feasibility Testing & Releases Second White Paper for its Planned Whole Transcriptome Panel Using HTG EdgeSeq Technology
TUCSON, Ariz., Feb. 26, 2021 (GLOBE NEWSWIRE) — HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today announced it has completed its feasibility testing for a planned whole transcriptome panel using the HTG EdgeSeq technology, and has released a follow-on whole transcriptome product white paper (White Paper Two), regarding the performance of a prototype panel for multiple cancer indications compared to RNA sequencing (RNA-Seq). HTG is developing a whole transcriptome panel using the HTG EdgeSeq technology to measure approximately 20,000 mRNA targets, with a planned research use only launch in the third quarter of 2021.Continue reading
Seven Arizona bio startups earn $30K through Flinn entrepreneurship program
Five Phoenix, two Tucson firms to receive personalized learning plan, other benefitsContinue reading
VectorCare and Life365 align to expand and accelerate the deployment of digital health solutions for healthcare organizations
The joint partnership between Life365 and VectorCare will enable healthcare organizations to create more efficient workflows and accelerate the deployment of digital health solutions. The companies saw an opportunity to provide remote health monitoring services to effectively treat and manage patients in their homes.